Skip to content
Global sound
Lab to Lives

Lab to Lives

Inside Sionna’s Bid To Normalize CFTR Function

· 30 min · Season 7 Episode 7

Show notes

Send us Fan Mail Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star. Visit: sionnatx.com Support the show ________ Reach out to Ivanna Rosendal Join the conversation on our LinkedIn page Visit www...

Live, last hour: 7,635 songs on 3,253 stations in 131 countries

Discover the world through radio

More ways to discover (9)

Heard something good? Save it, or open it straight away in Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
Expresión StereoContinue listening